PTO/SB/30 (04-07)

Approved for use through 09/30/2007, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are require	U.S. Patent and Trader red to respond to a collection of informa	mark Office; U.S. DEPARTMENT OF COMMERCE from unless it contains a valid OMB control number.		
Request	Application Number	10/716,095		
for Continued Examination (RCE) Transmittal Address to Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandra, VA 22313-1450	Filing Date	11/18/2003		
	First Named Inventor	Alexandra Kacmarek		
	Art Unit	1648		
	Examiner Name	Jeffrey S. Parkin		
	Attorney Docket Number	21489 US		
This is a Request for Continued Examination (RCE) u Request for Continued Examination (RCE) practice under 37 Cf 1995, or to any design application. See Instruction Sheet for RC	FR 1.114 does not apply to any util	ity or plant application filed prior to June 8,		
Submission required under 37 CFR 1.114 Not amendments enclosed with the RCE will be entered in the applicant does not wish to have any previously filed unen amendment(s).  Previously submitted If a final Office action is	e order in which they were filed uni tered amendment(s) entered, appl outstanding, any amendments filed	less applicant instructs otherwise. If icant must request non-entry of such		
considered as a submission even if this box is     Consider the arguments in the Appeal Br     Other     Enclosed	rief or Reply Brief previously filed o	n		
I. Amendment/Reply		Disclosure Statement (IDS)		
ii Affidavit(s)/ Declaration(s)				
The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled. The Director is hereby authorized to charge the following fees, any underpryment of fees, or credit any overpayments, to pepcial Account				
i X RCE fee required under 37 CFR 1.17(e)	(\$810.00)			
ii. x Extension of time fee (37 CFR 1.136 and 1	.17)			
III. Other				
b. Check in the amount of \$	enclosed			

c Payment by credit card (Form PTO-2039 enclosed)
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				
Signature	/ Samuel H. Megerditchtan /	Date	01/28/2008	
Name (Print/Type)	Samuel H. Megerdifichian	Registration No.	45,678	

CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposted with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop RCE, Commissioner for Petents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Signature Signature Samuel H. Meacrifichism?

This collection of information is required by 37 CPR 1.114. The information is required to obtain or return a benefit by the publish or the lot like the publish of the USPTC to process him application. Confidentiation is estimated to state 37 CPR 1.114 at this collection, is estimated to that in the process him application. Confidentiation is estimated to state 37 CPR 1.114 at 174. This collection is estimated to state instruction including gettlering, preparing, and submitting the completed application form to the USPTC. Time will vary depending upon the refundable state. Any comments or the amount of time vary required comments and the amount of time vary required comments and the confidence of the conf

Date

Name (Print/Type) Earnusi H (degreenthum

the amount of time you require to complete bits form and/or suggestions for neducing this busten, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Abscandia, VA 22313.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Mall Stop RCE, Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460. Under the Papervork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

## Instruction Sheet for RCEs

(not to be submitted to the USPTO)

## NOTES:

An RCE is not a new application, and filing an RCE will not result in an application being accorded a new filing date.

# Filing Qualifications:

The application must be a utility or plant application filed on or after June 8, 1995. The application cannot be a provisional application, a utility or plant application filed before June 8, 1995, a design application, or a patent under reexamination. See 37 CER 1.114(e).

## Filing Requirements:

Prosecution in the application must be closed. Prosecution is closed if the application is under appeal, or the last Office action is a final action, a notice of allowance, or an action that otherwise closes prosecution in the application (e.g., an Office action under Ex parte Quayle). See 37 CFR 1.114(b).

A submission and a fee are required at the time the RCE is filed. If reply to an Office action under 35 U.S.C. 132 is outstanding (e.g., the application is under final rejection), the submission must meet the reply requirements of 37 CFR 1.111. If there is no outstanding Office action, the submission can be an information disclosure statement, an amendment, new arguments, or new evidence. See 37 CFR 1.114(c). The submission may be a previously filed amendment (e.g., an amendment after final rejection).

## WARNINGS:

## Request for Suspension of Action:

All RCE filing requirements must be met before suspension of action is granted. A request for a suspension of action under 37 CFR 1.103(c) does <u>not</u> satisfy the submission requirement and does not permit the filing of the required submission to be suspended.

## Improper RCE will NOT toll Any Time Period:

Before Appeal - If the RCE is improper (e.g., prosecution in the application is not closed or the submission or fee has not been filed) and the application is not under appeal, the time period set forth in the last Office action will continue to run and the application will be abandoned after the statutory time period has expired if a reply to the Office action is not timely filed. No additional time will be given to correct the improper RCE.

Under Appeal - If the RCE is improper (e.g., the submission or the fee has not been filed) and the application is under appeal, the improper RCE is effective to withdraw the appeal. Withdrawal of the appeal results in the allowance or abandonment of the application depending on the status of the claims. If there are no allowed claims, the application is abandoned. If there is at least one allowed claim, the application will be passed to issue on the allowed claim(s). See MPEP 1215.01.

See MPEP 706.07(h) for further information on the RCE practice.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 36 L. 95. (2)(p.2) (2) furnishing of the information solicitied is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandoment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodutations.
- A feoord in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a/m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S C. 122(b) or issuance of a patient pursuant to 35 U.S C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.